Benzoylmesaconine

Benzoylmesaconine is a monoester-type alkaloid and is the most abundant component of Wutou decoction, which is widely used in China for rheumatoid arthritis. Benzoylmesaconine exhibits potent anti-inflammatory properties by inhibiting NF-κB. Benzoylmesaconine can suppress NLRP3 inflammasome activation by inhibiting IL-1β secretion and GSDMD-N protein expression. Benzoylmesaconine reduces intracellular K⁺ efflux and disrupts NLRP3 inflammasome assembly^[1][2][3]. In Vitro:Benzoylmesaconine (Compound BMA) (0-160 μM) effectively suppresses nigericin-induced IL-1β release in LPS-primed BMDMs in a concentration-dependent manner in bone marrow-derived macrophages (BMDMs)^[3].
Benzoylmesaconine (0-80 μM, 30 min) significantly inhibits the activation of caspase-1 and the secretion of IL-1β and key downstream effectors of the NLRP3 inflammasome in BMDMs^[3].
Benzoylmesaconine (0-80 μM) significantly reduces lactate dehydrogenase release and cell death, suggesting its ability to inhibit pyroptosis^[3]. In Vivo:Benzoylmesaconine (Compound BMA) (5-20 mg/kg, i.p., single dose) significantly reduces left hindfoot swelling and inflammatory cell infiltration in MSU-induced acute gouty arthritis mice compared to model group^[3].
Benzoylmesaconine (5-20 mg/kg, i.p., single dose) significantly inhibits DSS-induced colitis in mice model^[3].
Benzoylmesaconine (5-20 mg/kg, i.p., single dose) inhibits air pouch inflammation in MSU crystal induced air pouch mouse model^[3].